Protein-Related Technologies are deployed specifically for research and development of therapeutic proteins. Therapeutic proteins – signalling substances, enzymes and monoclonal antibodies – form by far the most important group of biotechnological agents in current use. Roche research has played a pivotal role in the use of protein-based therapeutics since the introduction of Roferon-A in 1986. These drugs usually display excellent affinity and selectivity for the disease target, favorable molecular properties and a low incidence of side effects. Roche owns and develops cutting edge protein-engineering technologies as well as world-class manufacturing processes and facilities. At Roche, we are actively working on the next wave of therapeutic proteins focusing on rational design, antibody engineering and new therapeutic modalities. In terms of sales, innovation potential and production capacity, Roche is the world’s largest biotech company.